27 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Selective Small-Molecule Inhibitors for theß-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.
University of Utah
Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
University of Utah
Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists ofß-catenin/TCF transcription.
University of Michigan
Direct targeting ofß-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling.
Chemical Genomics Centre of The Max Planck Society
Design, synthesis, and biological evaluation of novel 8-substituted quercetin derivatives targeting the β‑catenin/B-cell lymphoma 9 interaction.
Tongji University
Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
Fudan University
Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives.
Sichuan University
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.
Fudan University
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.
Ocean University of China
Targeting the interaction of β-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling.
Vu University Amsterdam
Biophysical Survey of Small-Molecule β-Catenin Inhibitors: A Cautionary Tale.
University of Southampton
Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
H. Lee Moffitt Cancer Center and Research Institute
Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.
H. Lee Moffitt Cancer Center and Research Institute
Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors.
University of Utah
Target β-catenin/CD44/Nanog axis in colon cancer cells by certain N'-(2-oxoindolin-3-ylidene)-2-(benzyloxy)benzohydrazides.
King Saud University
PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
Hoffmann-La Roche
Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
Genfleet Therapeutics (Shanghai)Inc.
NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
Ogeda
COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY
Case Western Reserve University
β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators
Samumed
Substituted 1H-indazol-1-OL analogs as inhibitors of beta catenin/Tcf protein-protein interactions
University of Utah
Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions
University of Utah